Aha1 Inhibitors Reduce Tau Aggregation in Neurodegenerative Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for tauopathies, such as Alzheimer's disease, lack disease-modifying therapies due to the inability of many Hsp90 inhibitors to cross the blood-brain barrier and their associated toxicities, and the need for effective reduction of tau aggregation.

Innovation Solution

Administration of Aha1 inhibitors, specifically compounds like KU-177, KU-174, or KU-308, which reduce tau aggregation by inhibiting the interaction between Aha1 and Hsp90, thereby reducing tauopathy progression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Hsp90 inhibitors are used to reduce tau aggregation, then tauopathy progression is slowed, but the inhibitors cannot cross the blood-brain barrier and exhibit high toxicity

Engineering Contradiction:

Improvetauopathy treatment efficacyVSAvoidtoxicity and blood-brain barrier impermeability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the toxic Hsp90 inhibitor from the system and replaces it with a non-toxic Aha1 inhibitor that achieves the same therapeutic effect of reducing tau aggregation without the harmful side effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces Aha1 as an intermediary target - instead of directly inhibiting Hsp90 (which causes toxicity), the invention uses Aha1 inhibitors that indirectly affect the Hsp90-tau pathway, achieving tau reduction through a safer intermediate mechanism

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Aha1 inhibitors are administered to reduce tau aggregation, then tauopathy progression is slowed, but the mechanism of action must be sufficiently potent to inhibit Aha1-Hsp90 interaction

Engineering Contradiction:

Improvetauopathy treatment efficacyVSAvoidmolecular interaction inhibition mechanism

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the molecular parameter being targeted from Hsp90 directly to Aha1, modifying the interaction parameters (binding affinity, inhibition constant) to achieve effective tau aggregation reduction while maintaining drug safety profiles

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If current Hsp90 inhibitors are used, then tau aggregation is targeted, but no disease-modifying treatments for Alzheimer's disease currently exist due to these limitations

Engineering Contradiction:

Improvedisease-modifying treatment capabilityVSAvoidclinical applicability

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent creates a copy of the therapeutic approach (inhibiting chaperone-mediated tau aggregation) but uses a different molecular target (Aha1 instead of Hsp90), replicating the beneficial effect while eliminating the limitations of the original approach

Inventive Principle:

Principle #26Copying

Data Source

PatentUS11931373B2HSP90 activator AHA1 drives production of pathological tau aggregates

Publication Date: 2024.03.19 UNIV OF SOUTH FLORIDA

AI summary

Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.